Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Rusthoven

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Chemotherapy and Pharmacology|December 3, 2005
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyJane E Latz, Mats O Karlsson, James J Rusthoven, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapyJane E Latz, James J Rusthoven, Mats O Karlsson, et al.
Cancer|July 27, 2004
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validationPatricia J Hollen, Richard J Gralla, Astra M Liepa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 7, 2005
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-MesoPatricia J Hollen, Richard J Gralla, Astra M Liepa, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed safety and dosing strategyClet Niyikiza, Axel-R Hanauske, James J Rusthoven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaNicholas J Vogelzang, James J Rusthoven, James Symanowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2023
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaNicholas J Vogelzang, James J Rusthoven, James Symanowski, et al.
Molecular Cancer Therapeutics|December 14, 2002
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapyClet Niyikiza, Sharyn D Baker, David E Seitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesotheliomaGiorgio V Scagliotti, Dong-M Shin, Hedy L Kindler, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Chemotherapy and Pharmacology|December 3, 2005
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapyJane E Latz, Mats O Karlsson, James J Rusthoven, et al.
Cancer Chemotherapy and Pharmacology|December 3, 2005
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapyJane E Latz, James J Rusthoven, Mats O Karlsson, et al.
Cancer|July 27, 2004
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validationPatricia J Hollen, Richard J Gralla, Astra M Liepa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 7, 2005
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-MesoPatricia J Hollen, Richard J Gralla, Astra M Liepa, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed safety and dosing strategyClet Niyikiza, Axel-R Hanauske, James J Rusthoven, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaNicholas J Vogelzang, James J Rusthoven, James Symanowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2023
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaNicholas J Vogelzang, James J Rusthoven, James Symanowski, et al.
Molecular Cancer Therapeutics|December 14, 2002
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapyClet Niyikiza, Sharyn D Baker, David E Seitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesotheliomaGiorgio V Scagliotti, Dong-M Shin, Hedy L Kindler, et al.
Pageof 1